tradingkey.logo
tradingkey.logo
Search

Transmedics Group Inc

TMDX
Add to Watchlist
67.850USD
+1.430+2.15%
Close 07/01, 16:00ETQuotes delayed by 15 min
2.34BMarket Cap
13.44P/E TTM

More Details of Transmedics Group Inc Company

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Inc Info

Ticker SymbolTMDX
Company nameTransmedics Group Inc
IPO dateMay 02, 2019
CEOHassanein (Waleed H)
Number of employees728
Security typeOrdinary Share
Fiscal year-endMay 02
Address200 Minuteman Road
CityANDOVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01810
Phone19785520900
Websitehttps://www.transmedics.com/
Ticker SymbolTMDX
IPO dateMay 02, 2019
CEOHassanein (Waleed H)

Company Executives of Transmedics Group Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
564.33K
+14.66%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
188.13K
+1.55%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
16.64K
+58.05%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
15.11K
+19.34%
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
14.35K
+57.82%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
6.98K
+41.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
5.79K
+50.48%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
3.00K
+88.95%
Dr. Tamer I. Khayal, M.D.
Dr. Tamer I. Khayal, M.D.
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Edward M. Basile
Mr. Edward M. Basile
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
564.33K
+14.66%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
188.13K
+1.55%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
16.64K
+58.05%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
15.11K
+19.34%
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
14.35K
+57.82%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
6.98K
+41.86%

FAQs

Who are the top five shareholders of Transmedics Group Inc?

The top five shareholders of Transmedics Group Inc are: Dr. Waleed H. Hassanein, M.D.

How many institutions hold shares of Transmedics Group Inc (TMDX)?

As of 2026Q1, 865 institutions hold shares of Transmedics Group Inc, with a combined market value of approximately 42.29M, accounting for 122.36% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1737478.00.

What is the biggest source of revenue for Transmedics Group Inc?

In 2026Q1, the OCS Liver net revenue business generated the highest revenue for Transmedics Group Inc, amounting to 460.53M and accounting for 76.58% of total revenue.